f424b3_103014.htm
Filed Pursuant to Rule 424(b)(3) and Rule 424(c)
Registration Statement No. 333-196235
 
October 30, 2014
 
PROSPECTUS SUPPLEMENT NO. 9


 
14,825,000 Shares of Common Stock
 
This prospectus supplement amends our prospectus dated June 19, 2014, as supplemented on July 15, 2014, July 21, 2014, August 6, 2014, August 8, 2014, September 26, 2014, October 1, 2014, October 8, 2014 and October 21, 2014 (the “Prospectus”) to allow the selling stockholders named in the Prospectus (the “Selling Stockholders”) to resell, from time to time, up to 14,825,000 shares of our common stock. The shares of our common stock covered by the Prospectus (the “Shares”) were issued by us to the selling stockholders in a private placement on May 20, 2014, as more fully described in the Prospectus.

This prospectus supplement is being filed to include the information set forth in our Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on October 30, 2014, which is set forth below. This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement.

Our shares of common stock are listed on the New York Stock Exchange (the “NYSE”) under the ticker symbol “PAH.”  The closing sale price on the NYSE for our shares of common stock on October 29, 2014 was $25.77 per share.
  
We are an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012.
 
Investing in our common stock involves risks.  You should carefully consider the risks that we have described in “Risk Factors” beginning on page 6 of the Prospectus, and under similar headings in any amendments or supplements to the Prospectus, before investing in the Shares.

Neither the SEC nor any state securities commission has approved or disapproved of these securities or determined if the Prospectus or this prospectus supplement is truthful or complete.  Any representation to the contrary is a criminal offense.

            You should rely only on the information contained in the Prospectus, this prospectus supplement or any future prospectus supplement or amendment.  Neither we nor the selling stockholders have authorized anyone to provide you with different information.  The selling stockholders are not making an offer of their Shares in any state where such offer is not permitted.


The date of this Prospectus Supplement No. 9 is October 30, 2014.

 
 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

 Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): October 24, 2014

 

 

Platform Specialty Products Corporation

(Exact name of registrant as specified in its charter)

 

Delaware 001-36272 37-1744899
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.

 

5200 Blue Lagoon Drive
Suite 855
Miami, Florida		 33126
(Address of Principal Executive Offices) (Zip Code)

 

Registrant’s telephone number, including area code: (203) 575-5850

 

Not Applicable
(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

Item 1.01 Entry into a Material Definitive Agreement.

 

As previously announced, on April 16, 2014, Platform Specialty Products Corporation (“Platform”) entered into a Stock and Asset Purchase Agreement (as amended, the “Purchase Agreement”) with Chemtura Corporation, on its own behalf and on behalf of certain of its subsidiaries (collectively, “Chemtura”) pursuant to which Platform agreed to acquire Chemtura’s agrochemicals business, Chemtura AgroSolutions (the “CAS Acquisition”), subject to customary closing conditions.

 

The parties intend to consummate the CAS Acquisition on or about November 3, 2014. As a result, on October 24, 2014, Platform and Chemtura entered into a letter agreement, pursuant to which the parties have agreed to irrevocably waive their respective rights to terminate the Purchase Agreement until November 8, 2014.

 

The foregoing description of the letter agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the letter agreement, a copy of which is filed herewith as Exhibit 2.1, and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit Number Exhibit Title
2.1 Letter agreement dated October 24, 2014 relating to the Stock and Asset Purchase Agreement, dated as of April 16, 2014, between Platform and Chemtura Corporation.

 

 

 
 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

  PLATFORM SPECIALTY PRODUCTS CORPORATION
     
     
October 30, 2014 By: /s/ Frank J. Monteiro
  Name: Frank J. Monteiro 
  Title: Senior Vice President and Chief Financial Officer

 

 

 

 

 

 
 

Exhibit Index

 

Exhibit Number Exhibit Title
2.1 Letter agreement dated October 24, 2014 relating to the Stock and Asset Purchase Agreement, dated as of April 16, 2014, between Platform and Chemtura Corporation.